WuXi Biologics Wins Top Jade Award at Asset ESG Awards 2026
Image
Shanghai – October 21, 2026 -- WuXi Biologics (2269.HK) won the Jade Award, the highest distinction at The Asset Corporate Sustainability Leadership Awards 2026, and was the only pharmaceutical company among this year's Jade recipients. The contract research, development and manufacturing organization (CRDMO) also took the Best in Transition (Hong Kong) award.
Jade Award rewards ESG integration into strategy and operations
The program confers the Jade Award on organizations that integrate sustainability into strategy and operations. Judging criteria include governance, resilience, innovation, transformation and long-term value creation. WuXi Biologics says the award reflects investor and industry recognition of its ESG governance and its use of sustainability to strengthen long-term competitiveness.